CS1 significantly enriched pathways for immune suppression in cancer and radiotherapy, while CS2 showed insensitivity to immunotherapy, and CS3 showed insensitivity to cell cycle-based radiotherapy. This evidence concerns the gene SLAMF7 and cancer.